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ABSTRACT
Objectives: This study aims to discuss the clinical, laboratory and genetic findings, and treatment options for six patients who were diagnosed with 
Blau syndrome (BS)/early-onset sarcoidosis (EOS).
Patients and methods: The study included four patients (2 males,2 females; mean age 7 years; range 4 to 10 years) with EOS and two siblings 
(1 male, 1 female; mean age 10 years; range, 9 to 11 years) with BS. Age, age of initial symptoms, age of diagnosis; articular involvement, presence of 
uveitis, dermatitis, or fever, other organ involvement, laboratory findings, results of metabolic tests for mucopolysaccharidosis and mucolipidosis, 
results of genetic, pathologic, and immunologic tests, radiologic findings to evaluate skeletal dysplasia, and treatment options were collected.
Results: The median age at diagnosis of all patients was 6 years (range, 1 to 10 years). Five patients had camptodactyly and bilateral boggy 
synovitis in the wrists and ankles, one had granulomatous inflammatory changes in the liver and kidney biopsy, and one had attacks of fever and 
granulomatous dermatitis. None had uveitis. The detected mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) were 
P268S (rs2066842), M513T (rs104895473), R702W (rs2066844), V955I (rs5743291), H343Y (rs199858111), and M491L (16:50745293). The treatments of 
patients included corticosteroids, non-steroid anti-inflammatory drugs, methotrexate, infliximab, adalimumab, anakinra, and canacinumab.
Conclusion: Camptodactyly and boggy synovitis are important signs of BS/EOS. Methotrexate and tumor necrosis factor blockers are more effective 
in patients with predominantly articular symptoms. In patients 5 and 6 and their mother, we determined a novel M491L mutation in the NOD2 gene. 
Currently, this work is in progress towards identifying the pathogenesis and treatment options for this disease.
Keywords: Blau syndrome, clinical findings, genetic, nucleotide-binding oligomerization domain containing 2.
Granulomatous autoinflammatory diseases 
are monogenic syndromes caused by mutations 
in the region encoding the nucleotide-binding 
domain of the nucleotide-binding oligomerization 
domain containing 2 (NOD2) gene, mapped 
to chromosome 16q12, as defined in 2001.1 
These syndromes are the familial and sporadic 
forms of the same disease (Blau syndrome [BS], 
online mendelian inheritance in man [OMIM] 
186580 and early-onset sarcoidosis [EOS], 
OMIM 609464). In 1985, pediatrician Edward 
Blau described the BS for the first time as 
a dominantly inherited, chronic inflammatory 
syndrome characterized by the clinical triad of 
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granulomatous dermatitis, symmetric arthritis, 
and recurrent uveitis with onset before four 
years of age.2 Most of the studies on BS/EOS 
are case reports in the literature. Until 2014, 
146 familial cases (BS) and 62 sporadic cases 
(EOS) with NOD2 mutations had been reported.3 
An international registry study group identified 
31 cases of BS from 11 countries in 2015.4 In 
2018, 50 BS cases with uveitis were reported 
from 25 clinical centers.5 In this study, we aimed 
to discuss the clinical, laboratory and genetic 
findings, and treatment options for six patients 
who were diagnosed with BS/EOS.
PATIENTS AND METHODS
This study was performed at the Department 
of Department of Child Health and Diseases, 
Division of Pediatric Rheumatology at Erciyes 
University Faculty of Medicine between May 
2013 and January 2017. The study included 
four patients (2 males, 2 females; mean age 
7 years; range 4 to 10 years) with EOS and two 
siblings (1 male, 1 female; mean age 10 years; 
range, 9 to 11 years) with BS. Patients' 
characteristics were obtained from patient 
charts. Age, age of initial symptoms, age 
of diagnosis; articular involvement, presence 
of uveitis, dermatitis, or fever, other organ 
involvement, laboratory findings, results of 
metabolic tests for mucopolysaccharidosis and 
mucolipidosis, results of genetic, pathologic, 
and immunologic tests, radiologic findings 
to evaluate skeletal dysplasia, and treatment 
options were collected. The study protocol was 
approved by the Erciyes University Faculty of 
Medicine Ethics Committee (29/09/2017-442). 
A written informed consent was obtained 
from the legal guardians of each patient. The 
study was conducted in accordance with the 
principles of the Declaration of Helsinki. 
Peripheral blood samples for deoxyribonucleic 
acid (DNA) extraction were obtained. The genomic 
DNA isolation and purification were performed 
using DNeasy Blood & Tissue Kit (Qiagen 
GmbH, Hilden, Germany). Quality control and 
quantitation of the isolated DNA sample were 
performed using a Nanodrop (Thermo Fisher 
Scientific, Wilmington, DE, USA). The structural 
integrity of the DNA sample was confirmed by gel 
electrophoresis.
We performed targeted gene sequencing for all 
NOD2 exonic and intronic regions in the 16q12.1 
(39.497 bp) genomic coordinate in all patients. 
Sequencing and bioinformatic data analysis were 
performed on an Illumina NextSeq500® according 
to the Illumina Nextera XT® Kit’s (Illumina Inc., 
San Diego, CA, USA) standard protocol as 
described previously.6
The sequencing data were aligned based 
on the GRCh37 human reference genome. A 
minimum depth of 200 reads was obtained for all 
sequences. Missense, splice site and stop codon 
variants, and frame shift and non-frame shift 
insertions and deletions were filtered according to 
1000 Genomes, Exome Aggregation Consortium, 
dbSNP138 and the ClinVar database based on 
a minor allele frequency below 1%. The sorting 
intolerant from tolerant and polymorphism 
phenotyping tools were used to assess the possible 
effects of the variants on the proteins.
RESULTS
Patient 1: A four-year-old male patient 
was referred for an evaluation for fever, 
lymphadenopathy, and non-pruritic skin eruption 
which was most prominent on the arms and 
legs. These symptoms began when the patient 
was four months old. The fever persisted for 
7-10 days, accompanied by a maculopapular rash, 
and cervical and axillary lymphadenopathy. The 
longest of the disease convalescence periods 
Figure 1. Maculopapular rash on patients’ legs.
119BS and EOS: A Six Case Series and Review of the Literature
was a month. He had no uveitis or articular 
involvement. There was no consanguinity or 
family history of any autoinflammatory disorders. 
A physical examination showed generalized, 
maculopapular eruption, particularly on the arms 
and legs, and an enlarged lymph node in the 
left cervical chain and axillary region (Figure 1). 
Laboratory tests conducted for etiology; complete 
blood count, blood smear, immunoglobulins, 
neutrophil function test by flow-cytometry, and a 
ratio of lymphocyst subgroups by flow-cytometry 
gave normal results. The serology of Epstein-
Barr virus, cytomegalovirus, toxoplasma, brucella, 
tularemia, Bartonella henselae, and results of the 
quantiferron test for tuberculosis were negative. 
A skin biopsy taken from a papule showed 
subepidermal non-Langerhans histiocytes and 
a non-caseating granuloma (Figure 2). A lymph 
node biopsy showed granulomatous inflammation 
as well (Figure 3). There was no mediastinal 
lymph node involvement on chest computed 
tomography. The NOD2 mutations detected 
were P268S (rs2066842, exon 4) and V955I 
(rs5743291, exon 9). The patient could not 
achieve remission with steroid, methotrexate, 
anakinra, adalimumab, and infliximab. He is still 
on a low dose steroid and canakinumab treatment.
Patient 2: A 10-year-old female patient was 
diagnosed with juvenile idiopathic arthritis (JIA) 
at the age of two. While she was on methotrexate 
and etanercept therapy, she developed multiorgan 
failure, and was referred to our department at the 
age of seven. Hepatic and renal biopsies revealed 
granulomatous inflammation in both organs. She 
had no uveitis. There was consanguinity but no 
family history. We re-evaluated her diagnosis 
due to polyarticular involvement, boggy synovitis 
on the wrists and ankles, camptodactyly, and 
the renal and hepatic biopsy results. The NOD2 
mutation detected was M513T (rs104895473, 
exon 4) heterozygote. The patient was put 
on methotrexate and infliximab, which led to 
remission.
Patient 3: A six-year-old female patient 
was admitted for polyarticular involvement, 
boggy synovitis on both wrists, camptodactyly, 
and hyperpigmented macular eruption on the 
anterior legs. Her complaints had started one 
year before. She was evaluated due to rapidly 
progressive deformities. Enzyme levels for 
mucopolysaccharidosis and mucolipidosis were 
in the normal ranges. Radiographic findings for 
skeletal dysplasia were normal. She had no uveitis. 
A skin biopsy could not be performed. There was 
no consanguinity or family history. The NOD2 
mutation detected was R702W (rs2066844, 
Figure 2. Skin biopsy showed granulomatous 
inflammation.
Figure 3. Lymph node biopsy showed granulomatous 
inflammation.
Figure 4. Camptodactyly and boggy synovitis in patient 6.
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exon 4) heterozygote. Remission was achieved 
with methotrexate.
Patient 4: An eight-year-old male patient 
was admitted for boggy synovitis on both wrists 
and legs, polyarthritis, and camptodactyly. His 
complaints started at nine months of age. He had 
no uveitis or dermatitis. There was consanguinity 
but no family history. He was evaluated due to 
mucopolysaccharidosis, mucolipidosis, and skeletal 
dysplasia. The NOD2 mutation detected was 
H343Y (rs199858111, exon 4). Remission could 
not be achieved with corticosteroids, methotrexate, 
etanercept, tocilizumab, adalimumab, infliximab, 
and canakinumab. He is on a low dose steroid and 
siklosporin treatment.
Patient 5: An 11-year-old male patient was 
admitted with boggy synovitis on both wrists 
and ankles, polyarthritis, and camptodactyly. 
His complaints started during infancy. There 
were no skin lesions or uveitis. The NOD2 
mutations detected were V955I (rs5743291, 
exon 9) and M491L (16:50745293, exon 4). 
There was no consanguinity. He was put on 
methotrexate and infliximab treatment, which 
led to remission.
Patient 6: A nine-year-old female patient 
was admitted with boggy synovitis on both wrists 
and ankles, polyarthritis, and camptodactyly 
(Figure 4). Her complaints started during 
infancy. There were no skin lesions or uveitis. 
There was no consanguinity. She is the sibling 
of patient 5. We screened the NOD2 gene 
and found the M491L (16:50745293, exon 4) 
mutation. To our knowledge, this mutation has 
not been reported before. She was put on 
methotrexate and infliximab treatment, which 
led to remission. 
The mother of patients 5 and 6 also had 
camptodactyly and articular complaints. The 
mother's NOD2 gene was found to have the 
M491L (16:50745293, exon 4) mutation, the 
same as in her daughter (patient 6). The father 
of patients 5 and 6 also had a V955I mutation 
in the NOD2 gene. The father did not have any 
complaints or clinical findings. The pedigree of 
patients 5 and 6 is shown as Figure 5.
All patients’ complete blood count, blood 
smears, immunoglobulin levels, urine calcium/
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enzyme levels, and enzyme levels for 
mucopolysaccharidosis and mucolipidosis were 
in the normal ranges (except for patient 1). 
Radiographic findings of the chest, extremities, 
and vertebrae were evaluated to exclude 
skeletal dysplasia (except for patient 1). The 
ophthalmological examinations of all patients had 
normal results. Tuberculin skin tests were negative 
Table 1. Clinical features of patients
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6/sibling 
of patient 5
Age (year)/sex 4/M 10/F 6/F 8/M 11/M 9/F
Age of initial symptoms 4 month 2 year 5 year 9 month Infancy Infancy
Age of diagnosis (year) 1 9 6 6 10 8
Fever + - - - - -
Arthritis - + + + + +
Dermatitis + - + - - -
Uveitis - - - - - -
Tenosynovitis - + + + + +
Camptodactyly - + + + + +
Kidney - + - - - -
Liver + - - - -
LAP + - - - - -
Lung - - - - - -
High APR + + - - - +
High ACE - - - - - -
Mutations P268S/V955I M513T/- R702W/SNP8 H343Y/- V955I/M491L M491L
MEFV mutations R761H/- - - E148Q/- E148Q/- -





NSAI, MTX NSAI, MTX, 
ETA, TOS, 
ADA, INF, CAN
NSAI, MTX NSAI, MTX
Current treatment LDS, CAN MTX, INF MTX LDS, 
Siklosporin
MTX, INF MTX, INF
LAP: Lymphadenopathy; APR: Acute Phase Reactans; ACE: Angiotensin converting enzyme; MEFV: Mediterranean fever; MTX: Methotrexate; ANA: 
Anakinra; ADA: Adalimumab; IFN: Infliximab; ETA: Etanercept; TOS: Tosilizumab; NSAI: Non-steroid anti-inflammatory drugs; CAN: Canakinumab; LDS: 
Low dose steroid.
Table 2. Genetic findings of patients





Exon 4 rs2066842 snv P/S C/T P268S Pathogenic BS/EOS
Exon 4 rs104895473 snv M/T T/C M513T Pathogenic BS/EOS
Exon 4 rs2066844 snv R/W C/T R702W Pathogenic BS/EOS
Exon 4 rs199858111 snv H/Y C/T H343Y Pathogenic BS/EOS
Exon 9 rs5743291 snv V/I G/A V955I Pathogenic BS/EOS
Exon 4 16:50745293 snv M/L A/T M491L US US
NOD2: Nucleotide-binding oligomerization domain containing 2; SNP: Single nucleotide polymorphism; snv: Single nucleotide variation; EOS: Early-onset 
sarcoidosis; US: Unknown significance.
Arch Rheumatol122
Table 3. Clinical features of patients receiving biologic therapy in the literature
Number of 
patients





Cuesta et al.25 3 Dermatitis, arthritis, uveitis ETA No










Arostegui et al.14 1 Fever, arthritis, papilledema R587C ANA Yes





















Yasui et al.28 2 1. Fever, dermatitis, arthritis, 
uveitis













































1 Uveitis - Methotrexate ETA, INF, ANA No




















































Rose et al.4 19 Arthritis,
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in all patients. The patients' clinical and laboratory 
findings are given in Table 1. The patients' genetic 
findings are provided in Table 2.
DISCUSSION
Blau syndrome and EOS are rare 
autoinflammatory systemic granulomatous 
diseases that have been associated with NOD2 
mutation. The NOD2 gene encodes a protein 
which is a member of the intracellular pattern-
recognition receptors family. This NOD2 
protein is involved in the inflammatory response 
through microbe-associated molecular pattern 
recognition.7 This protein is mainly expressed 
in monocytes, macrophages, and dendritic cells, 
and plays a crucial role in innate immune defense 
against invading pathogens. The engagement 
of the muramyl dipeptide ligand leads to the 
unfolding of NOD2 from its autoinhibited state.6 
The consequent activation of the key downstream 
signaling molecule nuclear factor kappa B (NF-kB) 
ultimately results in the production of inflammatory 
cytokines, chemokines, and adhesion molecules.7,8 
The NOD2 mutation is a gain of function mutation 
leading to hyperactivation of the NF-kB response.8
Blau syndrome and EOS are familial and 
sporadic forms of the same disease, respectively. 
The occurrence of BS/EOS is primarily among 
Caucasians, although it has been reported in 
Asians as well as Afro-Americans.9,10 There 
is no information about the distribution of 
the disease in the world. The classic BS/EOS 
symptom triad is skin rash, arthritis, and uveitis. 
Our sibling patients 5 and 6 and their mother 
were assessed as BS because of the familial 
form of the disease.
The disease begins typically before three-
four years of age.11 Onset occurs mostly with 
cutaneous and articular symptoms.12-15 However, 
symptoms sometimes appear after the age of 10.12 
Our patients' initial symptoms started between the 
age of four months and five years.
Two main types of symptomatic eruptions 
are reported: rash and multiple subcutaneous 
nodules. The rash usually appears as an 
erythema with maculopapular configuration. 
Pinhead-sized, lichenoid, yellow to brown papules 
typically appear in clusters and might become 
confluent. The appearance is variable, often 
symmetric, and is located on the trunk and/or 
extremities.16 Histology of the lesions consistently 
demonstrates non-caseating granulomas with 
multinucleated giant cells.17 BS is diagnosed with 
confirmatory histology in more than 90% of 
patients.13 A non-pruritic skin eruption was on the 
extremities of patients 1 and 3. Patient 1’s skin 
biopsy taken from a papule showed subepidermal 
non-Langerhans histiocytes and a non-caseating 
granuloma (Figure 2). This finding is characteristic 
of BS, and the skin biopsy gives a better diagnostic 
yield when compared to the synovium.13
Joint manifestations usually appear such as 














Nagakura et al.38 6 Arthritis,
Dermatitis (except 3 patients),






















1 Arthritis, dermatitis c.1808A>G Prednisolone
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ETA: Etanercept; TOS: Tosilizumab; ADA: Adalimumab; INF: Infliximab; CAN: Canakinumab; ANA: Anakinra.
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metacarpophalangeal, first metatarsophalangeal, 
and proximal interphalangeal (PIP) joints of 
the hands and feet, ankles, and occasionally 
the elbows. Contractures often develop in the 
PIP joints early in the course of the disease. 
This early deformity was originally described 
as camptodactyly.8 Additionally, granulomatous 
inflammation in the periarticular structures leads 
to marked periarticular swelling and tenosynovial 
cysts particularly affecting the wrists and dorsa of 
the hands.16 These appearances are characteristic 
phenotypic findings of the disease.8 Rosé et al.4 
reported that the characteristics of arthritis in BS, 
comprising boggy synovitis and tenosynovitis, 
are distinct from those observed in both JIA and 
rheumatoid arthritis. Despite the chronicity of 
exuberant arthritis, destruction of the larger joints 
is not commonly reported.8 Our patients’ most 
common manifestations were boggy synovitis 
and camptodactyly (Figure 4). These clinical 
findings allowed us to establish an early diagnosis 
for patients 3, 4, 5, and 6. Since camptodactyly 
with negative acute phase reactants should 
also be investigated for mucopolysaccharidosis, 
mucolipidosis, and skeletal dysplasia, our patients 
(except for patient 1) were investigated for these 
etiologies.
Eye symptoms generally appear later at 
around age 12.8 Uveitis presents as an insidious 
granulomatous iridocyclitis with posterior uveitis 
in many patients, and a potential evolution can 
be seen into severe panuveitis with multifocal 
choroiditis. It is usually bilateral and associated 
with an increased risk of visual morbidity.8 
Most patients require continuing follow-up and 
treatment for eye symptoms throughout their 
lives. Chorioretinitis, cataracts, glaucoma, and 
retinal detachment can lead to significant visual 
impairment and blindness.16 None of our patients 
had eye symptoms, and their regular ocular 
examinations were normal as a result of the early 
treatment. However, uveitis could be seen as a 
late finding of the disease in the future.
The presence of fever is determined in expanded 
manifestations.18 The main manifestation of 
the first patient was episodic fever, which was 
persistent for 7-10 days, accompanied by a 
rash. Aróstegui al.14 and Okafuji et al.15 also 
reported that 50% of their cohort had recurrent or 
persistent fever. These findings suggest that fever 
is one of the important symptoms of BS/EOS 
and is the reason why BS/EOS is misdiagnosed 
as systemic-onset JIA.15
Although interstitial pneumonitis and bronchial 
granulomas have been reported in patients with 
BS/EOS, the typical pulmonary involvement 
seen in patients with adult onset sarcoidosis 
has not been described.19,20 Granulomatous 
lymphadenopathy has been defined.20 Our 
patients did not have mediastinal lymph node or 
pulmonary involvement. There was cervical and 
axillary lymph node involvement accompanied by 
fever in patient 1. The lymph node biopsy showed 
non-caseating granulomatous inflammation in 
patient 1 (Figure 3).
Other expanded manifestations of BS/EOS 
are hepatosplenomegaly, sialadenitis, erythema 
nodosum, leukocytoclastic vasculitis, transient 
neuropathies, granulomatous glomerular and 
interstitial nephritis, arterial hypertension, 
pericarditis, pulmonary embolism, hepatic 
granulomas, splenic involvement, and chronic 
renal failure.8 Hepatic and renal failure developed 
in patient 2 due to the JIA treatment. Although 
both of her involvements were initially thought 
to be related to the etanercept treatment, 
camptodactyly and the biopsy findings helped us 
establish the correct diagnosis.
The most commonly detected NOD2 
mutations are R334W and R334Q.18 The 
patients' mutations were determined as follows: 
P268S (rs2066842), V955I (rs5743291), M513T 
(rs104895473), R702W (rs2066844), H343Y 
(rs199858111), and M491L (16:50745293). To 
our knowledge, the last mutation that was 
determined in patient 5, 6 and their mother 
has not been reported before. These family 
members were evaluated as having BS inherited 
as autosomal dominant. Although the penetrance 
of BS/EOS associated with NOD2 mutations is 
very high, asymptomatic family members with 
NOD2 mutations have been defined in the 
literature.21-23 The father of the patient 5, 6 
who had a V955I mutation did not have any 
symptoms. It is unclear whether the type and/or 
location of the NOD2 mutation has an effect 
on the clinical features.8 Rosé et al.18 concluded 
that the presence of overlapping clinical features 
supports the hypothesis that additional genetic 
factors might contribute to the phenotype in 
pediatric granulomatous inflammatory disease. 
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Therefore, we assessed Mediterranean fever 
(MEFV) mutations carried in up to 20% of 
healthy people in Turkey. However, we did not 
determine any significant MEFV mutations.
To the best of our knowledge, there has been 
no study on the optimal treatment for patients with 
BS/EOS, due to its rarity and the heterogeneity in 
its severity and the evolution of its expression. The 
main objective is to prevent ocular manifestations, 
which can be particularly severe.17 Low-dose 
glucocorticoids are generally satisfactory at the 
quiescent stage. In some acute stages, high doses 
of glucocorticoids are necessary. Methotrexate, 
corticosteroids, and tumor necrosis factor (TNF) 
inhibitors continue to be the main treatments.24 
The patients treated with biological therapy after 
2000 have been summarized in Table 3.25-41 
Although our patients with predominantly 
articular symptoms responded to methotrexate 
and TNF inhibitor therapies, we could not achieve 
remission with TNF, interleukin (IL)-6, or IL-1 
inhibitor therapies in patient 4. In addition, 
remission was achieved with a low dose steroid 
and canakinumab treatment for patient 1 without 
articular symptoms. There is no consensus on 
which IL pathway predominates in the literature. 
Galozzi et al.21 claimed that an exaggerated 
NOD2 response leading to pro-inflammatory 
release is not a direct mechanism explaining the 
pathophysiology of BS.
This study has some limitations. We could 
not carry out genetic tests on all family members 
except for the sibling patients and a functional 
analysis could not be performed for the new 
mutation.
In conclusion, camptodactyly and boggy 
synovitis are important signs of BS/EOS. 
Methotrexate and TNF blockers are more 
effective in patients with predominantly articular 
symptoms. Moreover, we determined a novel 
M491L mutation in the NOD2 gene. On the 
other hand, there is still no consensus on either 
the pathogenesis or treatment of BS/EOS in the 
literature, necessitating further studies. Currently, 
this work is in progress towards identifying the 
pathogenesis and treatment options.
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